beta

AKAO

Achaogen Inc.

Akao

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-08-2018 08-06-2018 after market close 05-04-2018 02-27-2018 after market close 11-08-2017 after market close 08-03-2017 after market close 05-08-2017 after market close
Actual EPS -0.88 -1.2 -0.98 -0.98 -0.85 -0.78 -0.51
Consensus EPS -0.96 -0.92 -0.91 -0.79 -0.72 -0.6 -0.51
Estimated EPS -0.96 -0.92 -0.91 -0.79 -0.72 -0.6 -0.51
Number of Estimates 7 6 6 7 6 7 6
EPS Surprise $0.08 -$0.28 -$0.07 -$0.19 -$0.13 -$0.18

Stats

Summary

Achaogen Inc is a biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections.

Market Cap: 468 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.achaogen.com

Shares Outstanding: 42.4 Million

Float: 36.4 Million

Dividend: 0.0 (0.0%)

Beta: 1.259079

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 10.7 Million

Ethical Flags

Animal testing

Longest drawdown: 725 trading days

From: 2014-03-24 To: 2017-02-07

Lowest Point:

Achaogen up 24% after FDA nod on plazomicin test

via: SeekingAlpha at 2018-12-10 15:33:18:000

Nano cap Achaogen ( AKAO +23.7% ) is up on double normal volume. This morning, it announced that the FDA has cleared Thermo Fisher Scientific's QMS Plazomicin Immunoassay that quantitatively measures the amount of plazomicin in human plasma. The test, performed on TMO's automated analyze… read more...

Healthcare and M&A stocks up in premarket trade

via: SeekingAlpha at 2018-12-10 09:11:41:000

Nutrisystem (NASDAQ: NTRI ) +31% on cash and stock offer from Tivity Health. More news on: Nutrisystem Inc, Mitek Systems Inc., Axsome Therapeutics, Stocks on the move, , Read more … read more...

Achaogen And Other Smallcaps With Approved Products Make Poor Investments

via: SeekingAlpha at 2018-11-26 20:37:11:000

Just today a TPT member asked me about Achaogen ( AKAO ) and whether the company is finished. Achaogen had its sole late-stage product plazomicin approved for cUTI (complicated urinary tract infection) in June 2018, but the FDA also rejected the product for bloodstream infections. The stock … read more...

Achaogen And Other Smallcaps With Approved Products Make Poor Investments

via: SeekingAlpha at 2018-11-26 20:37:11:000

Just today a TPT member asked me about Achaogen ( AKAO ) and whether the company is finished. Achaogen had its sole late-stage product plazomicin approved for cUTI (complicated urinary tract infection) in June 2018, but the FDA also rejected the product for bloodstream infections. The stock … read more...

Achaogen And Other Smallcaps With Approved Products Make Poor Investments

via: SeekingAlpha at 2018-11-26 20:37:11:000

Just today a TPT member asked me about Achaogen ( AKAO ) and whether the company is finished. Achaogen had its sole late-stage product plazomicin approved for cUTI (complicated urinary tract infection) in June 2018, but the FDA also rejected the product for bloodstream infections. The stock … read more...

Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector

via: SeekingAlpha at 2018-11-16 10:30:44:000

Perhaps one of the most negative developments that have happened this year on the biotech sector has been the collapse of once an industry darling: Synergy Pharmaceuticals ( SGYP ). The implications for the industry are far-reaching. As we have seen, one of the worst selloffs in biotechs has… read more...

Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector

via: SeekingAlpha at 2018-11-16 10:30:44:000

Perhaps one of the most negative developments that have happened this year on the biotech sector has been the collapse of once an industry darling: Synergy Pharmaceuticals ( SGYP ). The implications for the industry are far-reaching. As we have seen, one of the worst selloffs in biotechs has… read more...

Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector

via: SeekingAlpha at 2018-11-16 10:30:44:000

Perhaps one of the most negative developments that have happened this year on the biotech sector has been the collapse of once an industry darling: Synergy Pharmaceuticals ( SGYP ). The implications for the industry are far-reaching. As we have seen, one of the worst selloffs in biotechs has… read more...

Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector

via: SeekingAlpha at 2018-11-16 10:30:44:000

Perhaps one of the most negative developments that have happened this year on the biotech sector has been the collapse of once an industry darling: Synergy Pharmaceuticals ( SGYP ). The implications for the industry are far-reaching. As we have seen, one of the worst selloffs in biotechs has… read more...

Synergy Collapse Due To Toxic CRG Loan Sends Shockwaves Throughout Biotech Sector

via: SeekingAlpha at 2018-11-16 10:30:44:000

Perhaps one of the most negative developments that have happened this year on the biotech sector has been the collapse of once an industry darling: Synergy Pharmaceuticals ( SGYP ). The implications for the industry are far-reaching. As we have seen, one of the worst selloffs in biotechs has… read more...

JPMorgan downgrades Infinity Pharma to Underweight in premarket analyst action

via: SeekingAlpha at 2018-11-12 08:11:04:000

Adamis Pharmaceuticals (NASDAQ: ADMP ) downgraded to Neutral with a $2.50 (11% downside risk) price target at B. Riley FBR citing the slow ramp of Symjepi and soft performance of its compounding business. More news on: Adamis Pharmaceuticals Corp., Nobilis Health Corp., Infinity Pharmaceut… read more...

JPMorgan downgrades Infinity Pharma to Underweight in premarket analyst action

via: SeekingAlpha at 2018-11-12 08:11:04:000

Adamis Pharmaceuticals (NASDAQ: ADMP ) downgraded to Neutral with a $2.50 (11% downside risk) price target at B. Riley FBR citing the slow ramp of Symjepi and soft performance of its compounding business. More news on: Adamis Pharmaceuticals Corp., Nobilis Health Corp., Infinity Pharmaceut… read more...

JPMorgan downgrades Infinity Pharma to Underweight in premarket analyst action

via: SeekingAlpha at 2018-11-12 08:11:04:000

Adamis Pharmaceuticals (NASDAQ: ADMP ) downgraded to Neutral with a $2.50 (11% downside risk) price target at B. Riley FBR citing the slow ramp of Symjepi and soft performance of its compounding business. More news on: Adamis Pharmaceuticals Corp., Nobilis Health Corp., Infinity Pharmaceut… read more...

Achaogen (AKAO) CEO Blake Wise on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-08 14:02:06:000

Achaogen (AKAO) Q3 2018 Results Earnings Conference Call November 08, 2018, 08:30 AM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - CFO Analysts … read more...

Achaogen (AKAO) CEO Blake Wise on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-08 14:02:06:000

Achaogen (AKAO) Q3 2018 Results Earnings Conference Call November 08, 2018, 08:30 AM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - CFO Analysts … read more...

Achaogen (AKAO) CEO Blake Wise on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-08 14:02:06:000

Achaogen (AKAO) Q3 2018 Results Earnings Conference Call November 08, 2018, 08:30 AM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - CFO Analysts … read more...

Earnings movers dominate premarket losers list

via: SeekingAlpha at 2018-11-08 09:22:12:000

Achaogen (NASDAQ: AKAO ) -28% on Q3 earnings . More news on: Achaogen, Pyxus International, Inc., Zayo Group, Stocks on the move, , Top stock market news, Read more … read more...

Earnings movers dominate premarket losers list

via: SeekingAlpha at 2018-11-08 09:22:12:000

Achaogen (NASDAQ: AKAO ) -28% on Q3 earnings . More news on: Achaogen, Pyxus International, Inc., Zayo Group, Stocks on the move, , Top stock market news, Read more … read more...

Earnings movers dominate premarket losers list

via: SeekingAlpha at 2018-11-08 09:22:12:000

Achaogen (NASDAQ: AKAO ) -28% on Q3 earnings . More news on: Achaogen, Pyxus International, Inc., Zayo Group, Stocks on the move, , Top stock market news, Read more … read more...

Achaogen down 18% on Q3 results

via: SeekingAlpha at 2018-11-08 08:45:07:000

Achaogen ( AKAO ) Q3 results : Revenues: $2M. More news on: Achaogen, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Achaogen down 18% on Q3 results

via: SeekingAlpha at 2018-11-08 08:45:07:000

Achaogen ( AKAO ) Q3 results : Revenues: $2M. More news on: Achaogen, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Achaogen down 18% on Q3 results

via: SeekingAlpha at 2018-11-08 08:45:07:000

Achaogen ( AKAO ) Q3 results : Revenues: $2M. More news on: Achaogen, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Achaogen misses by $0.03, misses on revenue

via: SeekingAlpha at 2018-11-08 08:04:10:000

Achaogen (NASDAQ: AKAO ): Q3 GAAP EPS of -$1.02 misses by $0.03 . More news on: Achaogen, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Achaogen misses by $0.03, misses on revenue

via: SeekingAlpha at 2018-11-08 08:04:10:000

Achaogen (NASDAQ: AKAO ): Q3 GAAP EPS of -$1.02 misses by $0.03 . More news on: Achaogen, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Achaogen misses by $0.03, misses on revenue

via: SeekingAlpha at 2018-11-08 08:04:10:000

Achaogen (NASDAQ: AKAO ): Q3 GAAP EPS of -$1.02 misses by $0.03 . More news on: Achaogen, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Does Achaogen Have The Operational Runway Required To Deliver Value?

via: SeekingAlpha at 2018-11-07 09:10:32:000

Achaogen is not on the verge of bankruptcy We all know that the endless siren calls around Achaogen's ( AKAO ) relatively precarious financial position have been a major contributing factor to the stock's decline since the approval of Zemdri for cUTI, but not for BSI caused by CRE in the … read more...

Achaogen to explore strategic alternatives, shares up 6% premarket

via: SeekingAlpha at 2018-11-05 09:12:57:000

Achaogen (NASDAQ: AKAO ) announces that it has begun a review of strategic alternatives, including a possible sale or merger, aimed at boosting shareholder value. It has also begun downsizing the organization which should reduce operating expenses by 35 - 40%. The initiative should be comp… read more...

Achaogen to explore strategic alternatives, shares up 6% premarket

via: SeekingAlpha at 2018-11-05 09:12:57:000

Achaogen (NASDAQ: AKAO ) announces that it has begun a review of strategic alternatives, including a possible sale or merger, aimed at boosting shareholder value. It has also begun downsizing the organization which should reduce operating expenses by 35 - 40%. The initiative should be comp… read more...

Achaogen's Zemdri: Blockbuster Potential For A Pittance

via: SeekingAlpha at 2018-10-23 05:00:00:000

Introduction Achaogen ( AKAO ) is a commercial-stage drug developer based in the South San Francisco business park. Currently trading around $4/share, the company is valued at roughly $180m Mcap. The company had $100.5 million in cash, cash equivalents and short-term investments at 6/30/18 a… read more...

Achaogen's Zemdri: Blockbuster Potential For A Pittance

via: SeekingAlpha at 2018-10-23 05:00:00:000

Introduction Achaogen ( AKAO ) is a commercial-stage drug developer based in the South San Francisco business park. Currently trading around $4/share, the company is valued at roughly $180m Mcap. The company had $100.5 million in cash, cash equivalents and short-term investments at 6/30/18 a… read more...

Achaogen's Zemdri: Blockbuster Potential For A Pittance

via: SeekingAlpha at 2018-10-23 05:00:00:000

Introduction Achaogen ( AKAO ) is a commercial-stage drug developer based in the South San Francisco business park. Currently trading around $4/share, the company is valued at roughly $180m Mcap. The company had $100.5 million in cash, cash equivalents and short-term investments at 6/30/18 a… read more...

Contrafect: A New Anti-Microbial Treatment Paradigm

via: SeekingAlpha at 2018-10-11 10:51:26:000

Contrafect is a biotechnology firm addressing deadly infections with a paradigm shift in anti-infectives that utilize a recombinant biologic derived from viruses that attack bacteria Bacteriophage are to bacteria what viruses are to humans. Since their discovery in 1917, bacterial viruses … read more...

Contrafect: A New Anti-Microbial Treatment Paradigm

via: SeekingAlpha at 2018-10-11 10:51:26:000

Contrafect is a biotechnology firm addressing deadly infections with a paradigm shift in anti-infectives that utilize a recombinant biologic derived from viruses that attack bacteria Bacteriophage are to bacteria what viruses are to humans. Since their discovery in 1917, bacterial viruses … read more...

Contrafect: A New Anti-Microbial Treatment Paradigm

via: SeekingAlpha at 2018-10-11 10:51:26:000

Contrafect is a biotechnology firm addressing deadly infections with a paradigm shift in anti-infectives that utilize a recombinant biologic derived from viruses that attack bacteria Bacteriophage are to bacteria what viruses are to humans. Since their discovery in 1917, bacterial viruses … read more...

Forensic Stock Selections For October - Positive Forensic Returns Averaging +52.83%

via: SeekingAlpha at 2018-10-04 07:49:32:000

Forensic Value Stock Selections The following stocks selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year over year operational performance measures. The combination of all three bankruptcy and financial irregularity algori… read more...

Forensic Stock Selections For October - Positive Forensic Returns Averaging +52.83%

via: SeekingAlpha at 2018-10-04 07:49:32:000

Forensic Value Stock Selections The following stocks selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year over year operational performance measures. The combination of all three bankruptcy and financial irregularity algori… read more...

Forensic Stock Selections For October - Positive Forensic Returns Averaging +52.83%

via: SeekingAlpha at 2018-10-04 07:49:32:000

Forensic Value Stock Selections The following stocks selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year over year operational performance measures. The combination of all three bankruptcy and financial irregularity algori… read more...

Antibiotic developers in the green on Paratek news

via: SeekingAlpha at 2018-10-03 12:33:30:000

Stoked by the FDA nod for Paratek Pharmaceuticals' ( PRTK +7.4% ) NUZYRA (omadacycline), investors are spreading the love to certain other antibiotic makers. More news on: Paratek Pharmaceuticals, Inc., Achaogen, Tetraphase Pharmaceuticals, Healthcare stocks news, Stocks on the move, … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-28 08:57:51:000

Noteworthy events for the week of September 30 - October 6 for healthcare investors. More news on: Viking Therapeutics, Clementia Pharmaceuticals, Wave Life Sciences, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-28 08:57:51:000

Noteworthy events for the week of September 30 - October 6 for healthcare investors. More news on: Viking Therapeutics, Clementia Pharmaceuticals, Wave Life Sciences, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-28 08:57:51:000

Noteworthy events for the week of September 30 - October 6 for healthcare investors. More news on: Viking Therapeutics, Clementia Pharmaceuticals, Wave Life Sciences, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-28 08:57:51:000

Noteworthy events for the week of September 30 - October 6 for healthcare investors. More news on: Viking Therapeutics, Clementia Pharmaceuticals, Wave Life Sciences, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-09-28 08:57:51:000

Noteworthy events for the week of September 30 - October 6 for healthcare investors. More news on: Viking Therapeutics, Clementia Pharmaceuticals, Wave Life Sciences, Healthcare stocks news, , Read more … read more...

Entasis Therapeutics Readies $75 Million IPO Plan

via: SeekingAlpha at 2018-09-20 13:03:26:000

Quick Take Entasis Therapeutics ( ETTX ) intends to raise $75 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for treating antibiotic-resistant infectious diseases. ETTX has strong existing … read more...

Entasis Therapeutics Readies $75 Million IPO Plan

via: SeekingAlpha at 2018-09-20 13:03:26:000

Quick Take Entasis Therapeutics ( ETTX ) intends to raise $75 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for treating antibiotic-resistant infectious diseases. ETTX has strong existing … read more...

Entasis Therapeutics Readies $75 Million IPO Plan

via: SeekingAlpha at 2018-09-20 13:03:26:000

Quick Take Entasis Therapeutics ( ETTX ) intends to raise $75 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for treating antibiotic-resistant infectious diseases. ETTX has strong existing … read more...

The Waiting Is The Hardest Part - The Idea Guide

via: SeekingAlpha at 2018-09-07 14:52:12:000

Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o… read more...

The Waiting Is The Hardest Part - The Idea Guide

via: SeekingAlpha at 2018-09-07 14:52:12:000

Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o… read more...

The Waiting Is The Hardest Part - The Idea Guide

via: SeekingAlpha at 2018-09-07 14:52:12:000

Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o… read more...

The Waiting Is The Hardest Part - The Idea Guide

via: SeekingAlpha at 2018-09-07 14:52:12:000

Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o… read more...

The Waiting Is The Hardest Part - The Idea Guide

via: SeekingAlpha at 2018-09-07 14:52:12:000

Many stockpickers like to take credit for unearthing an idea, and expect that once they unearth it the market will have nothing to do but come to agree with you. And that does happen sometimes - a new idea can move the market and catalyze a change in perception, or at least start the process o… read more...

Achaogen Is A Victim Of Unfortunate Circumstances

via: SeekingAlpha at 2018-09-05 07:08:03:000

The following article will assess possible reasons shares of Achaogen ( AKAO ) have slipped, as well as assess Achaogen's near-term prospects in light of antibiotic sector sentiment and financial standings. Post-Approval/Post-Denial Since Zemdri was approved and denied for complicated… read more...

Achaogen Is A Victim Of Unfortunate Circumstances

via: SeekingAlpha at 2018-09-05 07:08:03:000

The following article will assess possible reasons shares of Achaogen ( AKAO ) have slipped, as well as assess Achaogen's near-term prospects in light of antibiotic sector sentiment and financial standings. Post-Approval/Post-Denial Since Zemdri was approved and denied for complicated… read more...

Achaogen Continues To Slide - How Much Farther Can It Go?

via: SeekingAlpha at 2018-08-27 11:47:13:000

Late in June, Achaogen (NASDAQ: AKAO ) announced that its lead drug candidate Zemdri (plazomicin) had been approved for the treatment of complicated urinary tract infections (cUTI) ; however, Zemdri had also received a CRL for the treatment of bloodstream infections ((BSI)). Though certa… read more...

Achaogen Continues To Slide - How Much Farther Can It Go?

via: SeekingAlpha at 2018-08-27 11:47:13:000

Late in June, Achaogen (NASDAQ: AKAO ) announced that its lead drug candidate Zemdri (plazomicin) had been approved for the treatment of complicated urinary tract infections (cUTI) ; however, Zemdri had also received a CRL for the treatment of bloodstream infections ((BSI)). Though certa… read more...

Achaogen Continues To Slide - How Much Farther Can It Go?

via: SeekingAlpha at 2018-08-27 11:47:13:000

Late in June, Achaogen (NASDAQ: AKAO ) announced that its lead drug candidate Zemdri (plazomicin) had been approved for the treatment of complicated urinary tract infections (cUTI) ; however, Zemdri had also received a CRL for the treatment of bloodstream infections ((BSI)). Though certa… read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Entasis Therapeutics files for $86.25M initial public offering

via: SeekingAlpha at 2018-08-17 18:15:29:000

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more … read more...

Achaogen (AKAO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:04:000

The following slide deck was published by Achaogen in conjunction with this Read more … read more...

Achaogen (AKAO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:04:000

The following slide deck was published by Achaogen in conjunction with this Read more … read more...

Achaogen (AKAO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:04:000

The following slide deck was published by Achaogen in conjunction with this Read more … read more...

Achaogen continues slide, down 9%

via: SeekingAlpha at 2018-08-13 11:05:50:000

Achaogen ( AKAO -9.2% ) is down on modestly higher volume. Shares have lost almost 60% of their value since touching $13.48 on June 21, the day after launching ZEMDRI (plazomicin) for the treatment of adults with complicated urinary tract infections and five days before announcing a restru… read more...

Achaogen continues slide, down 9%

via: SeekingAlpha at 2018-08-13 11:05:50:000

Achaogen ( AKAO -9.2% ) is down on modestly higher volume. Shares have lost almost 60% of their value since touching $13.48 on June 21, the day after launching ZEMDRI (plazomicin) for the treatment of adults with complicated urinary tract infections and five days before announcing a restru… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Achaogen's (AKAO) CEO Blake Wise on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 23:17:11:000

Achaogen (AKAO) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - Chief of Staff Analysts … read more...

Achaogen's (AKAO) CEO Blake Wise on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 23:17:11:000

Achaogen (AKAO) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - Chief of Staff Analysts … read more...

Achaogen's (AKAO) CEO Blake Wise on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 23:17:11:000

Achaogen (AKAO) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Gary Loeb - General Counsel Blake Wise - Chief Executive Officer Kenneth Hillan - President, R&D Janet Dorling - Chief Commercial Officer Zeryn Sarpangal - Chief of Staff Analysts … read more...

Achaogen misses by $0.28, beats on revenue

via: SeekingAlpha at 2018-08-06 16:02:30:000

Achaogen (NASDAQ: AKAO ): Q2 EPS of -$1.20 misses by $0.28 . Revenue of $2.6M (+104.7% Y/Y) beats by $1.24M . Press Release More news on: Achaogen, Earnings news and commentary, Healthcare stocks news, read more...

Achaogen Bags NTAP: Will It Help?

via: SeekingAlpha at 2018-08-06 15:09:24:000

After the disappointing label had become a fact for Achaogen's ( AKAO ) Zemdri, some investors had still hopes in the NTAP (new technology add-on payment) program. If granted, Zemdri could effectively achieve higher reimbursement rates. However, I had already alerted my subscribers that - even… read more...

Achaogen: Worth A Look At $7 Though Risks Persist

via: SeekingAlpha at 2018-08-01 15:21:49:000

For investors on the sidelines, shares of Achaogen Pharmaceuticals ( AKAO ) represent a very compelling opportunity at current prices. Though make no mistake, the road ahead will be a very long one and for that reason, I will recommend an options strategy at the end of this article to help inv… read more...

Achaogen: Worth A Look At $7 Though Risks Persist

via: SeekingAlpha at 2018-08-01 15:21:49:000

For investors on the sidelines, shares of Achaogen Pharmaceuticals ( AKAO ) represent a very compelling opportunity at current prices. Though make no mistake, the road ahead will be a very long one and for that reason, I will recommend an options strategy at the end of this article to help inv… read more...

Achaogen: Worth A Look At $7 Though Risks Persist

via: SeekingAlpha at 2018-08-01 15:21:49:000

For investors on the sidelines, shares of Achaogen Pharmaceuticals ( AKAO ) represent a very compelling opportunity at current prices. Though make no mistake, the road ahead will be a very long one and for that reason, I will recommend an options strategy at the end of this article to help inv… read more...

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance

via: SeekingAlpha at 2018-07-31 04:58:29:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene's Profits Reach Above Expectations For The Second-Quarter News: Recently, Celgene ( CELG ) reported profit that exceeded analysts' expectat… read more...

Achaogen restructures, shakes up management

via: SeekingAlpha at 2018-07-26 16:40:33:000

Aimed at sharpening its resources on building its ZEMDRI (plazomicin) business and developing C-Scape, Achaogen (NASDAQ: AKAO ) will restructure its operations, including a management shake-up. More news on: Achaogen, Healthcare stocks news, Read more … read more...

Achaogen restructures, shakes up management

via: SeekingAlpha at 2018-07-26 16:40:33:000

Aimed at sharpening its resources on building its ZEMDRI (plazomicin) business and developing C-Scape, Achaogen (NASDAQ: AKAO ) will restructure its operations, including a management shake-up. More news on: Achaogen, Healthcare stocks news, Read more … read more...

Achaogen restructures, shakes up management

via: SeekingAlpha at 2018-07-26 16:40:33:000

Aimed at sharpening its resources on building its ZEMDRI (plazomicin) business and developing C-Scape, Achaogen (NASDAQ: AKAO ) will restructure its operations, including a management shake-up. More news on: Achaogen, Healthcare stocks news, Read more … read more...

Achaogen launches ZEMDRI for use in cUTI; shares up 3% premarket

via: SeekingAlpha at 2018-07-20 08:25:37:000

Achaogen (NASDAQ: AKAO ) announces that ZEMDRI is now available for ordering in the U.S. FDA approved ZEMDRI is usedfor the treatment of adults with complicated Urinary Tract Infections (cUTI), including pyelonephritis, due to certain Enterobacteriaceae. More news on: Achaogen, Hea… read more...

Achaogen launches ZEMDRI for use in cUTI; shares up 3% premarket

via: SeekingAlpha at 2018-07-20 08:25:37:000

Achaogen (NASDAQ: AKAO ) announces that ZEMDRI is now available for ordering in the U.S. FDA approved ZEMDRI is usedfor the treatment of adults with complicated Urinary Tract Infections (cUTI), including pyelonephritis, due to certain Enterobacteriaceae. More news on: Achaogen, Hea… read more...

Achaogen launches ZEMDRI for use in cUTI; shares up 3% premarket

via: SeekingAlpha at 2018-07-20 08:25:37:000

Achaogen (NASDAQ: AKAO ) announces that ZEMDRI is now available for ordering in the U.S. FDA approved ZEMDRI is usedfor the treatment of adults with complicated Urinary Tract Infections (cUTI), including pyelonephritis, due to certain Enterobacteriaceae. More news on: Achaogen, Hea… read more...

Achaogen launches ZEMDRI for use in cUTI; shares up 3% premarket

via: SeekingAlpha at 2018-07-20 08:25:37:000

Achaogen (NASDAQ: AKAO ) announces that ZEMDRI is now available for ordering in the U.S. FDA approved ZEMDRI is usedfor the treatment of adults with complicated Urinary Tract Infections (cUTI), including pyelonephritis, due to certain Enterobacteriaceae. More news on: Achaogen, Hea… read more...

Achaogen launches ZEMDRI for use in cUTI; shares up 3% premarket

via: SeekingAlpha at 2018-07-20 08:25:37:000

Achaogen (NASDAQ: AKAO ) announces that ZEMDRI is now available for ordering in the U.S. FDA approved ZEMDRI is usedfor the treatment of adults with complicated Urinary Tract Infections (cUTI), including pyelonephritis, due to certain Enterobacteriaceae. More news on: Achaogen, Hea… read more...

Achaogen: Smaller Label, Unchanged Market?

via: SeekingAlpha at 2018-07-16 03:30:23:000

Last Thursday, Achaogen ( AKAO ) organized a lunch with two KOLs and analysts to inform the investment community on how the company is preparing for the commercialization of its recently approved antibiotic Zemdri. Looking at how the market reacted on Friday, sending the stock close to its… read more...

Achaogen: Smaller Label, Unchanged Market?

via: SeekingAlpha at 2018-07-16 03:30:23:000

Last Thursday, Achaogen ( AKAO ) organized a lunch with two KOLs and analysts to inform the investment community on how the company is preparing for the commercialization of its recently approved antibiotic Zemdri. Looking at how the market reacted on Friday, sending the stock close to its… read more...

Achaogen: Smaller Label, Unchanged Market?

via: SeekingAlpha at 2018-07-16 03:30:23:000

Last Thursday, Achaogen ( AKAO ) organized a lunch with two KOLs and analysts to inform the investment community on how the company is preparing for the commercialization of its recently approved antibiotic Zemdri. Looking at how the market reacted on Friday, sending the stock close to its… read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

via: SeekingAlpha at 2018-07-12 05:47:18:000

Obviously if you want to get good at something which is competitive, you have to think about it and practice a lot. You have to keep learning because the world keeps changing and competitors keep learning. You have to go to bed wiser than you got up. People who do that almost never fail utter… read more...

Achaogen to host lunch updating investors on commercial strategy post FDA approval of Plazomicin

via: SeekingAlpha at 2018-07-11 07:39:42:000

Achaogen (NASDAQ: AKAO ) will host a lunch updating investors on the market opportunities for plazomicin, including the treatment of serious bacterial infections due to MDR Enterobacteriaceae with perspectives from key opinion leaders Steven Burdette, M.D. and Joshua Rosenberg, M.D., on Thur… read more...

Achaogen: Zemdri To The Rescue

via: SeekingAlpha at 2018-07-10 16:25:52:000

Unable to pass up a bargain, I bought a few shares of Achaegen (AKAO) <$9.00 recently. Now, in a perfect example of backwardness, I am doing my more intensive due diligence. This article is my effort to evaluate the likely denouement of my rash behavior. Spoiler alert, I think it is going t… read more...

Midday Gainers / Losers (07/09/2018)

via: SeekingAlpha at 2018-07-09 12:42:43:000

Gainers: STAF +255% . BNTC +56% . EVK +26% . OTCPK:LFIN +17% . LEDS +15% . HELE +16% . NNDM +15% . TAT +14% . BBOX +12% . PVG +12% . More news on: Staffing 360 Solutions, Inc., Benitec, Ever-Glory International Group, Inc, Stocks on the move, , Rea… read more...

Is There Any Chance For New Antibiotics?

via: SeekingAlpha at 2018-07-06 12:17:16:000

The disconnect As many of my readers know, I have been closely following several of the biotechs that are developing new antibiotics. Over the past few years, I have written several articles on Paratek ( PRTK ), Nabriva ( NBRV ) and Achaogen ( AKAO ), while also taking a look at Melinta ( ML… read more...

Is There Any Chance For New Antibiotics?

via: SeekingAlpha at 2018-07-06 12:17:16:000

The disconnect As many of my readers know, I have been closely following several of the biotechs that are developing new antibiotics. Over the past few years, I have written several articles on Paratek ( PRTK ), Nabriva ( NBRV ) and Achaogen ( AKAO ), while also taking a look at Melinta ( ML… read more...

Is There Any Chance For New Antibiotics?

via: SeekingAlpha at 2018-07-06 12:17:16:000

The disconnect As many of my readers know, I have been closely following several of the biotechs that are developing new antibiotics. Over the past few years, I have written several articles on Paratek ( PRTK ), Nabriva ( NBRV ) and Achaogen ( AKAO ), while also taking a look at Melinta ( ML… read more...

Achaogen: Falling Knife Or Major Bargain?

via: SeekingAlpha at 2018-06-28 10:56:25:000

Jealousy is perhaps the most involuntary of all strong emotions. It steals consciousness, it lies deeper than thought. It is always there, like a blackness in the eye, it discolors the world . Iris Murdoch, The Sea, the Sea The shares on antibiotic concern Achaogen ( AKA… read more...

Achaogen: Falling Knife Or Major Bargain?

via: SeekingAlpha at 2018-06-28 10:56:25:000

Jealousy is perhaps the most involuntary of all strong emotions. It steals consciousness, it lies deeper than thought. It is always there, like a blackness in the eye, it discolors the world . Iris Murdoch, The Sea, the Sea The shares on antibiotic concern Achaogen ( AKA… read more...

Achaogen: Falling Knife Or Major Bargain?

via: SeekingAlpha at 2018-06-28 10:56:25:000

Jealousy is perhaps the most involuntary of all strong emotions. It steals consciousness, it lies deeper than thought. It is always there, like a blackness in the eye, it discolors the world . Iris Murdoch, The Sea, the Sea The shares on antibiotic concern Achaogen ( AKA… read more...

Your Daily Pharma Scoop: Glaukos And Achaogen Approvals, Puma Up On EU Prospects, FOLD Down

via: SeekingAlpha at 2018-06-28 08:00:00:000

Readers note: The Analysis Focus section is now only available to TPT subscribers . This follows the announcement from yesterday. Stocks in News: GKOS, AKAO Glaukos wins FDA approval for treatment managing glaucoma patients IOP Glaukos ( GKOS ) received FDA approval for it… read more...

Your Daily Pharma Scoop: Glaukos And Achaogen Approvals, Puma Up On EU Prospects, FOLD Down

via: SeekingAlpha at 2018-06-28 08:00:00:000

Readers note: The Analysis Focus section is now only available to TPT subscribers . This follows the announcement from yesterday. Stocks in News: GKOS, AKAO Glaukos wins FDA approval for treatment managing glaucoma patients IOP Glaukos ( GKOS ) received FDA approval for it… read more...

Your Daily Pharma Scoop: Glaukos And Achaogen Approvals, Puma Up On EU Prospects, FOLD Down

via: SeekingAlpha at 2018-06-28 08:00:00:000

Readers note: The Analysis Focus section is now only available to TPT subscribers . This follows the announcement from yesterday. Stocks in News: GKOS, AKAO Glaukos wins FDA approval for treatment managing glaucoma patients IOP Glaukos ( GKOS ) received FDA approval for it… read more...

Rounds Report: Spectrum To Potentially Enter Into A Merger & Acquisition

via: SeekingAlpha at 2018-06-28 00:28:55:000

The big money is not in the buying and selling. But in the waiting. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 26, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and… read more...

Rounds Report: Spectrum To Potentially Enter Into A Merger & Acquisition

via: SeekingAlpha at 2018-06-28 00:28:55:000

The big money is not in the buying and selling. But in the waiting. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 26, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and… read more...

Rounds Report: Spectrum To Potentially Enter Into A Merger & Acquisition

via: SeekingAlpha at 2018-06-28 00:28:55:000

The big money is not in the buying and selling. But in the waiting. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 26, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and… read more...

Achaogen (AKAO) FDA Approval - Slideshow

via: SeekingAlpha at 2018-06-27 13:08:06:000

The following slide deck was published by Achaogen in conjunction with this Read more … read more...

Biotech Analysis Central Pharma News: Puma's Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen's FDA Score

via: SeekingAlpha at 2018-06-27 07:02:19:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. European Advisory Committee Reverses Course Of Puma's Breast Cancer Drug News: On Monday, Puma Biotechnology ( PBYI ) announced that the committee of… read more...

Achaogen down 20% after FDA approval

via: SeekingAlpha at 2018-06-26 13:56:49:000

The approval for Zemdri was just for urinary tract infections, but not bloodstream infections. Also the label will exclude data from the Phase 3 "Care" trial. More news on: Achaogen, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket Losers as of 9:05 am (6/26/2018)

via: SeekingAlpha at 2018-06-26 09:25:13:000

XBIO -22% retreating after yesterday's gain. More news on: Xenetic Biosciences, Inc., Achaogen, Gevo, Inc., Stocks on the move, Read more … read more...

Achaogen's Zemdri antibiotic approved by FDA for urinary tract infections

via: SeekingAlpha at 2018-06-26 08:23:42:000

Achaogen (NASDAQ: AKAO ) says the U.S. Food and Drug Administration has approved its Zemdri (plazomicin) antibiotic to treat adults with complicated urinary tract infections; shares are halted. More news on: Achaogen, Healthcare stocks news, Read more … read more...

Stocks To Watch: More Trade Tiffs And Stress Tests

via: SeekingAlpha at 2018-06-23 08:49:01:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger … read more...

Stocks To Watch: More Trade Tiffs And Stress Tests

via: SeekingAlpha at 2018-06-23 08:49:01:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger … read more...

Stocks To Watch: More Trade Tiffs And Stress Tests

via: SeekingAlpha at 2018-06-23 08:49:01:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger … read more...

Your Daily Pharma Scoop: Reata Begins New Trial, CytoDyn Amends Protocol, Argenx Reports Positive Data

via: SeekingAlpha at 2018-06-22 12:14:28:000

Analysis Focus: RETA Reata Pharmaceuticals (NASDAQ: RETA ) begins Phase 1 clinical trial to evaluate the safety and pharmacokinetics of RTA 1701. RTA 1701 is one of a series of highly selective and orally bioavailable allosteric inhibitors of RORyt. The series has the potential to treat … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-01 11:18:05:000

Noteworthy events during the week of June 3 - 9 for healthcare investors. More news on: Jazz Pharmaceuticals, Inc., TherapeuticsMD, Bristol-Myers Squibb Company, Healthcare stocks news, , Read more … read more...

Achaogen: Buy Before The June 25 PDUFA Date

via: SeekingAlpha at 2018-05-24 14:29:52:000

Achaogen (AKAO) is a clinical-stage biotechnology company specializing in creating antibiotics to treat MDR (multidrug resistant) bacteria. Its lead candidate, plazomicin, recently was recommended for approval for cUTI (complicated urinary tract infections) on May 2 by an FDA advisory commit… read more...

Achaogen: Buy Before The June 25 PDUFA Date

via: SeekingAlpha at 2018-05-24 14:29:52:000

Achaogen (AKAO) is a clinical-stage biotechnology company specializing in creating antibiotics to treat MDR (multidrug resistant) bacteria. Its lead candidate, plazomicin, recently was recommended for approval for cUTI (complicated urinary tract infections) on May 2 by an FDA advisory commit… read more...

Achaogen: Buy Before The June 25 PDUFA Date

via: SeekingAlpha at 2018-05-24 14:29:52:000

Achaogen (AKAO) is a clinical-stage biotechnology company specializing in creating antibiotics to treat MDR (multidrug resistant) bacteria. Its lead candidate, plazomicin, recently was recommended for approval for cUTI (complicated urinary tract infections) on May 2 by an FDA advisory commit… read more...

Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech

via: SeekingAlpha at 2018-05-23 09:58:06:000

Tetraphase Pharmaceuticals (TTPH) is a small cap company developing antibiotics to address the growing plague of antibiotic-resistant bacterial diseases. Diseases that were becoming rare are now becoming more common because the bacteria that cause them evolved to tolerate a range of standard a… read more...

Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech

via: SeekingAlpha at 2018-05-23 09:58:06:000

Tetraphase Pharmaceuticals (TTPH) is a small cap company developing antibiotics to address the growing plague of antibiotic-resistant bacterial diseases. Diseases that were becoming rare are now becoming more common because the bacteria that cause them evolved to tolerate a range of standard a… read more...

Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech

via: SeekingAlpha at 2018-05-23 09:58:06:000

Tetraphase Pharmaceuticals (TTPH) is a small cap company developing antibiotics to address the growing plague of antibiotic-resistant bacterial diseases. Diseases that were becoming rare are now becoming more common because the bacteria that cause them evolved to tolerate a range of standard a… read more...

Lucky Seven: Bio Struggles, Achaogen Breaks Key Support

via: SeekingAlpha at 2018-05-21 23:22:11:000

Micron's ( MU ) raise before earnings and softened trade-war talk with China may have shifted money towards tech and away from biotech. Or, at least, it's nice to think that way. Not only did we see a sea of red, but we saw a member of the green boxes say, in capital letters, "EW". How rud… read more...

Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds

via: SeekingAlpha at 2018-05-19 16:35:08:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky st… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

via: SeekingAlpha at 2018-05-16 03:55:30:000

Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc… read more...

Lucky Seven: Achaogen Likely To Bounce Back

via: SeekingAlpha at 2018-05-14 08:19:53:000

The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C… read more...

Lucky Seven: Achaogen Likely To Bounce Back

via: SeekingAlpha at 2018-05-14 08:19:53:000

The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C… read more...

Achaogen: Explicating The Prospects Of C-Scape

via: SeekingAlpha at 2018-05-13 06:36:09:000

Long ago, Ben Graham taught me that Price is what you pay; value is what you get. Whether were talking about socks or stocks, I like buying quality merchandise when it is marked down. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar investment for opportun… read more...

Achaogen: Explicating The Prospects Of C-Scape

via: SeekingAlpha at 2018-05-13 06:36:09:000

Long ago, Ben Graham taught me that Price is what you pay; value is what you get. Whether were talking about socks or stocks, I like buying quality merchandise when it is marked down. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar investment for opportun… read more...

Achaogen: A Long-Term Holding With Tremendous Prospects

via: SeekingAlpha at 2018-05-11 02:50:09:000

Most people are too fretful, they worry too much. Success means being very patient, but aggressive when its time. - Charlie Munger Achaogen (NASDAQ: AKAO ) is a stellar investing opportunity that suffered a temporary depreciation and thereby became a significant bargain with mu… read more...

Achaogen: A Long-Term Holding With Tremendous Prospects

via: SeekingAlpha at 2018-05-11 02:50:09:000

Most people are too fretful, they worry too much. Success means being very patient, but aggressive when its time. - Charlie Munger Achaogen (NASDAQ: AKAO ) is a stellar investing opportunity that suffered a temporary depreciation and thereby became a significant bargain with mu… read more...

Daily Insider Ratings Round Up 5/7/18: TSLA, TEGP, CVS, NHF, FLDM, AKAO, EYES, MDB

via: SeekingAlpha at 2018-05-09 09:36:57:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 5/7/18: TSLA, TEGP, CVS, NHF, FLDM, AKAO, EYES, MDB

via: SeekingAlpha at 2018-05-09 09:36:57:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Achaogen: In The Middle Of A Temporary Difficulty There Is A Stellar Opportunity

via: SeekingAlpha at 2018-05-09 02:19:27:000

Be fearful when others are greedy and greedy when others are fearful. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar bioscience that is quite volatile. Investors who are not the faint of heart can accumulate shares after the recent pullback for the potential to earn multiple fo… read more...

Achaogen: In The Middle Of A Temporary Difficulty There Is A Stellar Opportunity

via: SeekingAlpha at 2018-05-09 02:19:27:000

Be fearful when others are greedy and greedy when others are fearful. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar bioscience that is quite volatile. Investors who are not the faint of heart can accumulate shares after the recent pullback for the potential to earn multiple fo… read more...

Iterum Therapeutics Plans $92 Million IPO

via: SeekingAlpha at 2018-05-07 12:02:55:000

Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci… read more...

Iterum Therapeutics Plans $92 Million IPO

via: SeekingAlpha at 2018-05-07 12:02:55:000

Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci… read more...

Achaogen After Ad Comm

via: SeekingAlpha at 2018-05-07 10:38:59:000

Always forgive your enemies; nothing annoys them so much . Oscar Wilde Late last Tuesday, Achaogen ( AKAO ) got a mixed result from the Ad Comm Panel around its primary drug candidate Plazomicin. The good news was the panel voted unanimously in a 15-0 vote to recommend… read more...

Achaogen's (AKAO) CEO Blake Wise On Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-04 15:12:05:000

Achaogen (AKAO) Q1 2018 Earnings Conference Call May 4, 2018, 08:30 AM ET Executives Gary Loeb - General Counsel Blake Wise - CEO Kenneth Hillan - President, Research and Development Janet Dorling - CCO Toby Schilke - CFO Analysts Stephen Willey - Stifel Ami Fadia - L… read more...

Midday Gainers / Losers (05/03/2018)

via: SeekingAlpha at 2018-05-04 12:58:29:000

Gainers: VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, … read more...

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

via: SeekingAlpha at 2018-02-13 12:46:16:000

Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Aradigm: Points Of Discussion

via: SeekingAlpha at 2018-02-02 13:29:55:000

As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm ( ARDM ) investors to consider. First, the CRL: The recommendations in the CRL include an independent third party verificati… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

via: SeekingAlpha at 2018-02-01 08:00:00:000

Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 30, 2018

via: SeekingAlpha at 2018-01-31 09:31:59:000

Market and sector outlook: Another down day for the U.S. equity indexes ( SPY ) (advances: declines= 0.20: 0.73) but we hope another new high. VIX was up 6.8%. High yield bonds ( HYG ) were down 0.34% and is at 50-DMA support (further support at 87.08). 10-year yield was slightly down (2…. read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 30, 2018

via: SeekingAlpha at 2018-01-31 09:31:59:000

Market and sector outlook: Another down day for the U.S. equity indexes ( SPY ) (advances: declines= 0.20: 0.73) but we hope another new high. VIX was up 6.8%. High yield bonds ( HYG ) were down 0.34% and is at 50-DMA support (further support at 87.08). 10-year yield was slightly down (2…. read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 30, 2018

via: SeekingAlpha at 2018-01-31 09:31:59:000

Market and sector outlook: Another down day for the U.S. equity indexes ( SPY ) (advances: declines= 0.20: 0.73) but we hope another new high. VIX was up 6.8%. High yield bonds ( HYG ) were down 0.34% and is at 50-DMA support (further support at 87.08). 10-year yield was slightly down (2…. read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

via: SeekingAlpha at 2018-01-16 08:54:15:000

Biotech: a never-ending story Investing is a never-ending story, a matter of keeping up to date and anticipating important developments. This is particularly true of the ultra-dynamic biotech sector. 2017 was a remarkable year which saw the coming-of-age of CAR-T immuno-oncology, import… read more...

Achaogen (AKAO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-12 14:15:48:000

The following slide deck was published by Achaogen in conjunction with this Read more … read more...

After Hours Gainers / Losers (1/10/2018)

via: SeekingAlpha at 2018-01-10 17:35:42:000

Top gainers: PRGS +7.6% . NVAX +4.7% . MFIN +4.3% . KBH +3.8% . STKL +3.1% . More news on: Progress Software Corporation, Novavax, Inc., Medallion Financial, Stocks on the move, Read more … read more...

Zymeworks - Protein Proficiency At A Discount

via: SeekingAlpha at 2018-01-09 16:29:44:000

Introduction Therapeutic antibodies, derived from human immunoglobin, remain the dominant weapon in our arsenal of large-molecule biologics aimed at everything from cancer over infectious disease to auto-immune disorders. Monoclonal antibodies were first synthesized in 1975, and the FDA firs… read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Daily Insider Ratings Round Up 1/5/18: AKAO, SHAK, CODI, IRET, SWZ, MSF

via: SeekingAlpha at 2018-01-08 12:13:29:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

ROTY Edition 1 Volume 68: An Exciting New Position And Other Updates

via: SeekingAlpha at 2018-01-08 04:58:15:000

Welcome to the 68th entry in our Runner of the Year ((ROTY)) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primar… read more...

Biotech Analysis Central Pharma News: Protalix Phase 2 Success, Achaogen NDA Acceptance, GW Pharmaceuticals FDA Advance

via: SeekingAlpha at 2018-01-03 15:08:19:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Protalix BioTherapeutics Announces Positive Data For Phase 2 Ulcerative Colitis Trial News: On Monday, Protalix BioTherapeutics ( PLX ) announced posi… read more...

3 Things In Biotech You Should Learn Today: January 3, 2018

via: SeekingAlpha at 2018-01-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Novartis scores an important first in CML Company: Novartis ( NVS ) Therapy: Niloti… read more...

ROTY Edition 1 Volume 67: Starting January On A Strong Note

via: SeekingAlpha at 2018-01-03 07:41:09:000

Welcome to the 67th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full-position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX